# Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections

> **NCT01077245** · PHASE2 · WITHDRAWN · sponsor: **Osel, Inc.**

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** MIYA-BM Fine Granules (CBM588)
- **DRUG:** Placebo Fine Granules (without CBM588)

## Key facts

- **NCT ID:** NCT01077245
- **Lead sponsor:** Osel, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-02
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077245, "Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01077245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*